PEPTONIC medical has concluded a preference share emission which gave 13,6 MSEK.
During October 2012 a preference share emission was finished giving 13,6 MSEK. This constituted the possibilities for PEPTONIC to conclude the clinical dose-finding study, development of better application system, a new formulation for administration on the skin and for planning of the phase III study together with a partner.
